6 years of historical data (2019–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Prime Medicine, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $833M | $346M | $806M | $1.8B | — | — | — |
| Enterprise Value | $691M | $205M | $778M | $1.6B | — | — | — |
| P/E Ratio → | -2.80 | — | — | — | — | — | — |
| P/S Ratio | 279.26 | 116.10 | — | — | — | — | — |
| P/B Ratio | 3.58 | 2.26 | 6.06 | 5.71 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 68.60 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Prime Medicine, Inc. earns an operating margin of -6787.4%. A negative ROE of -136.9% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | — | 42.8% | — |
| Operating Margin | -6787.4% | -6787.4% | — | — | — | -17.9% | — |
| Net Profit Margin | -6566.6% | -6566.6% | — | — | — | -65.5% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -136.9% | -136.9% | -88.2% | -43.8% | -121.1% | -19.6% | -182.1% |
| ROA | -79.7% | -79.7% | -71.5% | -36.8% | -92.7% | -10.7% | -29.1% |
| ROIC | -260.5% | -260.5% | -117.0% | -78.8% | -207.6% | — | — |
| ROCE | -102.0% | -102.0% | -87.0% | -40.4% | -60.5% | -5.1% | -156.4% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $182M exceeds total debt of $41M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.27 | 0.10 | 0.09 | 0.04 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.93 | -0.21 | -0.50 | -0.73 | -1.10 | -6.23 |
| Net Debt / EBITDA | — | — | — | — | — | — | -1.99 |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — |
Net cash position: cash ($182M) exceeds total debt ($41M)
Short-term solvency ratios and asset-utilisation metrics
Prime Medicine, Inc.'s current ratio of 5.58x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 11.10x to 5.58x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 5.58 | 5.58 | 2.53 | 11.10 | 4.67 | 2.75 | 1.19 |
| Quick Ratio | 5.58 | 5.58 | 2.53 | 11.10 | 4.67 | 2.75 | 1.19 |
| Cash Ratio | 5.02 | 5.02 | 2.16 | 11.00 | 4.65 | 2.74 | 1.18 |
| Asset Turnover | — | 0.01 | — | — | — | 0.10 | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Prime Medicine, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $119M | $91M | $97M | $96M | $96M | $96M |
Compare PRME with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| PRMEYou | $833M | -2.8 | — | — | 100.0% | -6787.4% | -136.9% | -260.5% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 6 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PRME stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonPrime Medicine, Inc.'s current P/E ratio is -2.8x. This places it at the 50th percentile of its historical range.
Prime Medicine, Inc.'s return on equity (ROE) is -136.9%. The historical average is -98.6%.
Based on historical data, Prime Medicine, Inc. is trading at a P/E of -2.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Prime Medicine, Inc. has 100.0% gross margin and -6787.4% operating margin.